Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors
Human RAD9 is a key cell-cycle checkpoint protein that participates in DNA repair, activation of multiple cell cycle phase checkpoints, and apoptosis. Aberrant RAD9 expression has been linked to breast, lung, thyroid, skin, and prostate tumorigenesis. Overexpression of RAD9 interacts with BCL-2 prot...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Journal of Chemistry |
| Online Access: | http://dx.doi.org/10.1155/2013/679459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556210675515392 |
|---|---|
| author | Nirmal K. Prasad Vishnupriya Kanakaveti Siddhartha Eadlapalli Ramakrishna Vadde Angamba Potshangbam Meetei Vaibhav Vindal |
| author_facet | Nirmal K. Prasad Vishnupriya Kanakaveti Siddhartha Eadlapalli Ramakrishna Vadde Angamba Potshangbam Meetei Vaibhav Vindal |
| author_sort | Nirmal K. Prasad |
| collection | DOAJ |
| description | Human RAD9 is a key cell-cycle checkpoint protein that participates in DNA repair, activation of multiple cell cycle phase checkpoints, and apoptosis. Aberrant RAD9 expression has been linked to breast, lung, thyroid, skin, and prostate tumorigenesis. Overexpression of RAD9 interacts with BCL-2 proteins and blocks the binding sites of BCL-2 family proteins to interact with chemotherapeutic drugs and leads to drug resistance. Focusing on this interaction, the present study was designed to identify the interaction sites of RAD9 to bind BCL-2 protein and also to inhibit RAD9-BCL-2 interactions by designing novel small molecule inhibitors using pharmacophore modeling and to restore BCL-2 for interacting with anticancer drugs. The bioactive molecules of natural origin act as excellent leads for new drug development. Thus, in the present study, we used the compounds of natural origin like camptothecin, ascididemin, and Dolastatin and also compared them with synthetic molecule NSC15520. The results revealed that camptothecin can act as an effective inhibitor among all the ligands taken and can be used as an RAD9 inhibitor. The amino acids ARG45 and ALA134 of RAD9 protein are interacting commonly with the drugs and BCL-2 protein. |
| format | Article |
| id | doaj-art-aa8490edd4a34fbfa1d6fd2e323ec559 |
| institution | Kabale University |
| issn | 2090-9063 2090-9071 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Chemistry |
| spelling | doaj-art-aa8490edd4a34fbfa1d6fd2e323ec5592025-02-03T05:46:04ZengWileyJournal of Chemistry2090-90632090-90712013-01-01201310.1155/2013/679459679459Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 InhibitorsNirmal K. Prasad0Vishnupriya Kanakaveti1Siddhartha Eadlapalli2Ramakrishna Vadde3Angamba Potshangbam Meetei4Vaibhav Vindal5Department of Biotechnology & Bioinformatics, Yogi Vemana University, Kadapa 516003, IndiaDepartment of Biotechnology & Bioinformatics, Yogi Vemana University, Kadapa 516003, IndiaDepartment of Biotechnology & Bioinformatics, Yogi Vemana University, Kadapa 516003, IndiaDepartment of Biotechnology & Bioinformatics, Yogi Vemana University, Kadapa 516003, IndiaDepartment of Biotechnology, School of Life Sciences, University of Hyderabad, Hyderabad 500046, IndiaDepartment of Biotechnology, School of Life Sciences, University of Hyderabad, Hyderabad 500046, IndiaHuman RAD9 is a key cell-cycle checkpoint protein that participates in DNA repair, activation of multiple cell cycle phase checkpoints, and apoptosis. Aberrant RAD9 expression has been linked to breast, lung, thyroid, skin, and prostate tumorigenesis. Overexpression of RAD9 interacts with BCL-2 proteins and blocks the binding sites of BCL-2 family proteins to interact with chemotherapeutic drugs and leads to drug resistance. Focusing on this interaction, the present study was designed to identify the interaction sites of RAD9 to bind BCL-2 protein and also to inhibit RAD9-BCL-2 interactions by designing novel small molecule inhibitors using pharmacophore modeling and to restore BCL-2 for interacting with anticancer drugs. The bioactive molecules of natural origin act as excellent leads for new drug development. Thus, in the present study, we used the compounds of natural origin like camptothecin, ascididemin, and Dolastatin and also compared them with synthetic molecule NSC15520. The results revealed that camptothecin can act as an effective inhibitor among all the ligands taken and can be used as an RAD9 inhibitor. The amino acids ARG45 and ALA134 of RAD9 protein are interacting commonly with the drugs and BCL-2 protein.http://dx.doi.org/10.1155/2013/679459 |
| spellingShingle | Nirmal K. Prasad Vishnupriya Kanakaveti Siddhartha Eadlapalli Ramakrishna Vadde Angamba Potshangbam Meetei Vaibhav Vindal Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors Journal of Chemistry |
| title | Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors |
| title_full | Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors |
| title_fullStr | Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors |
| title_full_unstemmed | Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors |
| title_short | Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors |
| title_sort | ligand based pharmacophore modeling and virtual screening of rad9 inhibitors |
| url | http://dx.doi.org/10.1155/2013/679459 |
| work_keys_str_mv | AT nirmalkprasad ligandbasedpharmacophoremodelingandvirtualscreeningofrad9inhibitors AT vishnupriyakanakaveti ligandbasedpharmacophoremodelingandvirtualscreeningofrad9inhibitors AT siddharthaeadlapalli ligandbasedpharmacophoremodelingandvirtualscreeningofrad9inhibitors AT ramakrishnavadde ligandbasedpharmacophoremodelingandvirtualscreeningofrad9inhibitors AT angambapotshangbammeetei ligandbasedpharmacophoremodelingandvirtualscreeningofrad9inhibitors AT vaibhavvindal ligandbasedpharmacophoremodelingandvirtualscreeningofrad9inhibitors |